Cargando…

Immune checkpoints, their control by immunotherapy and ovarian cancer

Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovar...

Descripción completa

Detalles Bibliográficos
Autor principal: Bose, Chinmoy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701579/
https://www.ncbi.nlm.nih.gov/pubmed/29180924
http://dx.doi.org/10.5114/wo.2017.70108
_version_ 1783281369644793856
author Bose, Chinmoy K.
author_facet Bose, Chinmoy K.
author_sort Bose, Chinmoy K.
collection PubMed
description Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovarian cancer. As a new development this subject is experiencing rapid progress and multiple avenues are opening up. However, there are many hurdles to overcome, requiring constant updating, especially for students of ovarian cancer, who are looking at it with much hope.
format Online
Article
Text
id pubmed-5701579
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-57015792017-11-27 Immune checkpoints, their control by immunotherapy and ovarian cancer Bose, Chinmoy K. Contemp Oncol (Pozn) Review Paper Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovarian cancer. As a new development this subject is experiencing rapid progress and multiple avenues are opening up. However, there are many hurdles to overcome, requiring constant updating, especially for students of ovarian cancer, who are looking at it with much hope. Termedia Publishing House 2017-09-29 2017 /pmc/articles/PMC5701579/ /pubmed/29180924 http://dx.doi.org/10.5114/wo.2017.70108 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Bose, Chinmoy K.
Immune checkpoints, their control by immunotherapy and ovarian cancer
title Immune checkpoints, their control by immunotherapy and ovarian cancer
title_full Immune checkpoints, their control by immunotherapy and ovarian cancer
title_fullStr Immune checkpoints, their control by immunotherapy and ovarian cancer
title_full_unstemmed Immune checkpoints, their control by immunotherapy and ovarian cancer
title_short Immune checkpoints, their control by immunotherapy and ovarian cancer
title_sort immune checkpoints, their control by immunotherapy and ovarian cancer
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701579/
https://www.ncbi.nlm.nih.gov/pubmed/29180924
http://dx.doi.org/10.5114/wo.2017.70108
work_keys_str_mv AT bosechinmoyk immunecheckpointstheircontrolbyimmunotherapyandovariancancer